Clearpoint Common Stock Total Equity from 2010 to 2024
| CLPT Stock | USD 12.37 0.26 2.15% |
Common Stock Total Equity | First Reported 2011-12-31 | Previous Quarter 246 K | Current Value 246 K | Quarterly Volatility 255 K |
Check Clearpoint Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearpoint Neuro's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 366.7 K or Selling General Administrative of 7.5 M, as well as many indicators such as Price To Sales Ratio of 7.13, Dividend Yield of 0.0 or PTB Ratio of 8.29. Clearpoint financial statements analysis is a perfect complement when working with Clearpoint Neuro Valuation or Volatility modules.
Clearpoint | Common Stock Total Equity |
Latest Clearpoint Neuro's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Clearpoint Neuro over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Clearpoint Neuro's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clearpoint Neuro's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Clearpoint Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 306,916 | |
| Geometric Mean | 225,357 | |
| Coefficient Of Variation | 83.77 | |
| Mean Deviation | 200,551 | |
| Median | 221,400 | |
| Standard Deviation | 257,099 | |
| Sample Variance | 66.1B | |
| Range | 877.6K | |
| R-Value | (0.29) | |
| Mean Square Error | 65B | |
| R-Squared | 0.09 | |
| Significance | 0.29 | |
| Slope | (16,886) | |
| Total Sum of Squares | 925.4B |
Clearpoint Common Stock Total Equity History
About Clearpoint Neuro Financial Statements
Clearpoint Neuro shareholders use historical fundamental indicators, such as Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although Clearpoint Neuro investors may analyze each financial statement separately, they are all interrelated. The changes in Clearpoint Neuro's assets and liabilities, for example, are also reflected in the revenues and expenses on on Clearpoint Neuro's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 221.4 K | 263.6 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.